Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of the MANIFEST phase 2 study Meeting Abstract
| Authors: | Gupta, V.; Kremyanskaya, M.; Mascarenhas, J.; Palandri, F.; Patriarca, A.; Devos, T.; Harrison, C.; Passamonti, F.; Rampal, R.; Mead, A.; Scandura, J.; Hobbs, G.; Talpaz, M.; Granacher, N.; Somervaille, T.; Hoffman, R.; Bose, P.; Colak, G.; Shao, J.; Cui, J. K.; Bobba, S.; Luptakova, K.; Verstovsek, S. |
| Abstract Title: | Clinical benefit of pelabresib (CPI-0610) in combination with ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis patients: Interim efficacy subgroup analysis from Arm 3 of the MANIFEST phase 2 study |
| Meeting Title: | 9th Annual Meeting of the Society of Hematologic Oncology (SOHO) |
| Keywords: | myelofibrosis; epigenetic; ruxolitinib; mpn; pelabresib; manifest |
| Journal Title: | Clinical Lymphoma, Myeloma and Leukemia |
| Volume: | 21 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2021 Sep 8-11 |
| Meeting Location: | Virtual event |
| ISSN: | 2152-2650 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2021-09-01 |
| Start Page: | S362 |
| Language: | English |
| ACCESSION: | WOS:000691910500271 |
| PROVIDER: | wos |
| DOI: | 10.1016/s2152-2650(21)01833-4 |
| Notes: | Meeting Abstract: MPN-332 -- Source: Wos |
